Wockhardt (WOCKPHARMA) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2024.

• Results reviewed by Audit Committee and subjected to limited review by statutory auditors, with no material misstatements identified.

Financial highlights

• Standalone revenue from operations for Q3 FY25 was Rs 325 crore, down from Rs 370 crore in Q2 FY25 but up from Rs 288 crore in Q3 FY24.

• Standalone net loss for Q3 FY25 was Rs 22 crore, compared to a net loss of Rs 36 crore in Q2 FY25 and Rs 74 crore in Q3 FY24.

• Consolidated revenue from operations for Q3 FY25 was Rs 729 crore, compared to Rs 809 crore in Q2 FY25 and Rs 701 crore in Q3 FY24.

• Consolidated net profit after tax for Q3 FY25 was Rs 20 crore, compared to a net loss of Rs 16 crore in Q2 FY25 and a net loss of Rs 86 crore in Q3 FY24.

• For the nine months ended December 31, 2024, consolidated net loss after tax was Rs 12 crore, a significant improvement from Rs 295 crore loss in the same period last year.

Outlook and guidance

• No explicit forward-looking guidance provided, but improved consolidated profitability in Q3 FY25 signals positive momentum.